Natco Pharma Limited has informed the Exchange regarding a press release dated September 02, 2021, titled "Natco Pharma (Canada) Inc. announces the launch of PrNAT-LENALIDOMIDE Capsules, the first generic alternative to Revlimid��".
Press Release Sep 02 2021
Filed with NSE · · 3 pages · English
Summary by 6ix AI
NATCO Pharma Limited has issued a press release announcing the launch of NAT-LENALIDOMIDE Capsules, the first generic alternative to Revlimid approved by Health Canada. This product aims to provide affordable treatment options for patients with multiple myeloma and transfusion-dependent anemia due to myelodysplastic syndromes. The launch represents a significant milestone in NATCO's efforts to expand its product portfolio and improve access to high-quality medicines in Canada.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Earlier from NATCO Pharma
- Press Release Aug 20 2021
- Press Release Aug 03 2021
- Press Release Jul 07 2021
- Press Release Jun 14 2021
- Press Release May 22 2021
Later from NATCO Pharma
- Press Release Oct 01 2021
- Natco Pharma launches Everolimus tablets 10 mg in US market
- Press Release Nov 18 2021
- Press Release Dec 28 2021
- NATCO Pharma receives approval for Molnupiravir Capsules 200 mg for the treatment of Covid-19 in India
Follow NATCO Pharma into a list and get an email when it puts out news.
Follow NATCO Pharma